> CPDR News
Dr Bungo Furusato Wins Outstanding Poster Award
7th Society for Urologic Oncology Annual Meeting December 1-2, 2005, Natcher Conference Center, NIH, Bethesda, Maryland
November 4, 2005
CPDR is pleased to announce that Dr Bungo Furusato, Staff Scientist, CPDR/AFIP wins the outstanding poster award at the 7th Society for Urologic Oncology Annual meeting December 1-2, 2005, Natcher Conference Center NIH Bethesda Maryland. For his poster presentation. The research was carried out under the direction of Dr Srivastava CPDR and Dr Sesterhenn, AFIP.
The title and abstract of his poster presented at the meeting
GENE EXPRESSION SIGNATURES IN BENIGN AND MALIGNANT EPITHELIAL CELLS FROM FORMALIN-FIXED PARAFFIN-EMBEDDED (FFPE) TISSUES OF PROSTATE CANCER PATIENTS
BUNGO FURUSATO 1, 2, SYED SHAHEDUZZAMAN 2, GYORGY PETROVICS 2, VASANTHA SRIKANTAN 2, LAKSHMI RAVINDRANATH 2, MARTIN E. NAU 3, MARYANNE VAHEY 3, DAVID G. MCLEOD 4, SHIV SRIVASTAVA 2 AND ISABELL A. SESTERHENN 1
1 DEPARTMENT OF GENITOURINARY PATHOLOGY, ARMED FORCES INSTITUTE OF PATHOLOGY; 2 CENTER FOR PROSTATE DISEASE RESEARCH, DEPARTMENT OF SURGERY, USUHS; 3 AFFYMETRIX GENE ARRAY LABORATORY, DIVISION OF RETROVIROLGY, WRAIR; 4 UROLOGY SERVICE, WALTER REED ARMY MEDICAL CENTER.
Introduction & Objectives: We have focused on discovery of Prostate Cancer (CaP) gene specific expression biomarkers using OCT embedded frozen prostate tissue specimens, laser-capture micro-dissections (LCM) and GeneChips. The ability to use clinical specimens for GeneChip assays, such as formalin fixed paraffin embedded (FFPE) tissues, will enhance and integrate the discovery of clinically relevant diagnostic/prognostic markers for CaP. This is a feasibility study for evaluating CaP associated gene expression signatures in FFPE CaP tissues.
Methods: Matched benign and malignant epithelial cells were obtained from 7-micron sections of FFPE whole-mounted radical prostatectomy specimen, which included the site from which frozen tissue was retrieved for an earlier GeneChip study. LCM derived epithelial cells from benign and malignant glands were analyzed by Affymetrix HG U133a and Human X3P GeneChips and tumor cell specific gene expression signatures were evaluated using the GeneSpring software (Silicon Genetics). The results were compared to GeneChip data from corresponding frozen prostate tissue specimens embedded in OCT.
Results: Evaluation of the expression patterns in paired benign and malignant epithelial cells from FFPE was compared with GeneChip data from corresponding frozen tissue specimens. Analysis of gene expression patterns in LCM derived epithelial cells from FFPE tissues revealed similarity to a subset of genes exhibiting tumor cell specific differential expression in the study of LCM derived benign and malignant cells from frozen OCT- embedded prostate tissues. This subset of 224 genes included AMACR, ERG1, HOXC6, NPY, CLDN8, CCT6A, MYO6, FOLH1, TMSNB, SUMO2, and PAP. Among these genes, apoptosis regulators, growth/DNA synthesis promoters, antioxidant response modulators, cell-cell adhesion molecules and transcription factors showed similar expression patterns between FPPE and OCT embedded frozen tissues.
Conclusions: Our preliminary studies provide proof of principle that FFPE cap tissue can be used for cell specific gene expression analysis. This will help us to validate the utility and limitation of FFPE cap tissues. Utilization of FFPE tissue for genechip studies will enhance the pathologic correlations of cap associated gene expression biomarkers; especially for cancer specimens linked to long term follow-ups, generally not available in frozen tissue banks.
The CPDR mission is fulfilled primarily through its three principal programs – the Clinical Research Center, the Basic Science Research Program and the National Multicenter Prostate Cancer Database– and through a robust education and training program that operates out of its Headquarters location, the Clinical Research Center, and the original laboratories at USUHS. CPDR is also committed to patient outreach, primarily through its affiliation with the WRAMC US TOO! organization and through a heavy schedule of health fairs in which it participates.
